

September 3, 2020

# CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including Citi's 15<sup>th</sup> Annual BioPharma Conference taking place September 9-10, 2020, the H.C. Wainwright 22<sup>nd</sup> Annual Global Investment Conference taking place September 14-16, 2020 and the Cantor Global Healthcare Conference taking place September 15-17, 2020.

## ***Citi's 15<sup>th</sup> Annual BioPharma Conference***

Date: Wednesday, September 9  
Time: 1-on-1 meetings only

## ***H.C. Wainwright 22<sup>nd</sup> Annual Global Healthcare Conference***

Date: Monday, September 14  
Time: 1:30 pm Eastern Time  
Webcast: <http://ir.cymabay.com/events>

## ***Cantor Global Healthcare Conference***

Date: Wednesday, September 16  
Time: 10:40 am Eastern Time  
Webcast: <http://ir.cymabay.com/events>

## About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPAR $\delta$  agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA and PRiority MEDicines status from the EMA for PBC.

## Cautionary Statements

Any statements made in this press release and at the investor conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, CymaBay's expectations and plans regarding its intended future interactions with the FDA, its current and future clinical trials and CymaBay's ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not

be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide or to potentially restart clinical trials. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit [www.cymabay.com](http://www.cymabay.com).

**Public Relations Contact:**

Glenn Silver  
Lazar-FINN Partners  
(973) 818-8198  
[Glenn.silver@finnpartners.com](mailto:Glenn.silver@finnpartners.com)

**Investor Relations Contact:**

Hans Vitzthum  
LifeSci Advisors, LLC  
(617) 430-7578  
[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)



Source: CymaBay Therapeutics, Inc.